ARTICLE | Clinical News
MOR209/ES414: Phase I started
March 23, 2015 7:00 AM UTC
Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Product: MOR209/ES414 (formerly ES414) Business: Cancer Molecular target: Prostate-s...